Biomarkers and Case Reports


Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo a rigorous assessment before and after licensure to minimize safety concerns. Potential safety concerns should be identified as early as possible during the development of vaccines and biologicals to minimize investment risk. State-of-the-art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions.


    Related Conference of Biomarkers and Case Reports

    May 30-31, 2024

    World congress on Immunology and Virology Diseases

    Vienna, Austria
    August 01-02, 2024

    44th Global Summit and Expo on Vaccines & Immunology

    Montreal, Canada
    September 09-10, 2024

    4th International Conference on Vaccine Research

    Madrid, Spain
    November 28-29, 2024

    6th World Congress on Vaccine and Immunology

    Paris, France

    Biomarkers and Case Reports Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in